Baxter Healthcare’s treatment of short bowel syndrome was granted FDA orphan designation, according to a post to the agency’s website. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
- Baxter call volume above normal and directionally bullish
- Baxter price target lowered to $54 from $63 at Barclays
- Baxter price target lowered to $45 from $70 at Cowen
- Baxter Crumbles as Projections Disappoint, Job Cuts Planned
- Baxter put volume heavy and directionally bearish
Questions or Comments about the article? Write to editor@tipranks.com